HomeInsightsStock Comparison

Glenmark Pharmaceuticals Ltd vs Lupin Ltd Stock Comparison

Glenmark Pharmaceuticals Ltd vs Lupin Ltd Stock Comparison

Last Updated on: Sep 28, 2025

Key Highlights

  • The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 1970 as of 26 Sep 15:30.
  • The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 7.5 on March 2020 to 41.5 on March 2025 . This represents a CAGR of 32.99% over 6 yearsThe P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 28.2 on March 2025 . This represents a CAGR of -5.84% over 5 years.
  • The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 5814 crore on March 2020 to ₹ 43458 crore on March 2025 . This represents a CAGR of 39.83% over 6 yearsThe Market Cap of Lupin Ltd changed from ₹ 26713 crore on March 2020 to ₹ 92522 crore on March 2025 . This represents a CAGR of 23.00% over 6 years.
  • The revenue of Glenmark Pharmaceuticals Ltd for the Jun '25 is ₹ 3290 crore as compare to the Mar '25 revenue of ₹ 3267 crore. This represent the growth of 0.7% The revenue of Lupin Ltd for the Jun '25 is ₹ 6347 crore as compare to the Mar '25 revenue of ₹ 5724 crore. This represent the growth of 10.89%.
  • The ebitda of Glenmark Pharmaceuticals Ltd for the Jun '25 is ₹ 283.73 crore as compare to the Mar '25 ebitda of ₹ 199.89 crore. This represent the growth of 41.94% The ebitda of Lupin Ltd for the Jun '25 is ₹ 1806 crore as compare to the Mar '25 ebitda of ₹ 1378 crore. This represent the growth of 31.07%.
  • The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 173.13 crore to ₹ 46.97 crore over 9 quarters. This represents a CAGR of -44.00% The net profit of Lupin Ltd changed from ₹ 453.33 crore to ₹ 1221 crore over 9 quarters. This represents a CAGR of 55.35% .
  • The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 5.21 % on March 2020 to 4.38 % on March 2025 . This represents a CAGR of -2.85% over 6 yearsThe Dividend Payout of Lupin Ltd changed from 37.36 % on March 2020 to 13.79 % on March 2025 . This represents a CAGR of -15.30% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
  • The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.

About Lupin Ltd

  • Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
  • The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
  • In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
  • In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

Glenmark Pharmaceuticals Ltd News Hub

News

Board of Glenmark Pharmaceuticals recommends interim dividend

Glenmark Pharmaceuticals announced that the Board of Directors of the Company at its meeti...

Read more

26 Sep 2025 11:56

News

Glenmark inks license and collaboration agreement with Hengrui Pharma

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals (Gle...

Read more

24 Sep 2025 16:08

News

Glenmark Pharmaceuticals to conduct board meeting

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2...

Read more

23 Sep 2025 09:49

News

Glenmark Pharmaceuticals receives affirmation in credit rating from CRISIL

Glenmark Pharmaceuticals announced that CRISIL has reaffirmed the credit rating for the ba...

Read more

19 Sep 2025 10:33

News

Glenmark Pharma to transfer its consumer care biz to Glenmark Consumer Care

Glenmark Pharmaceuticals announced that a Business Transfer Agreement for transfer of the ...

Read more

15 Sep 2025 18:01

News

Ichnos Glenmark Innovation receives upfront payment of USD700 million

Ichnos Glenmark Innovation (IGI), Glenmark's wholly owned subsidiary, has received an upfr...

Read more

09 Sep 2025 09:06

Lupin Ltd News Hub

News

Lupin gains after USFDA clears HIV drug for tentative launch

The drug is the generic version of Biktarvy Tablets (50 mg/200 mg/25 mg), marketed by Gile...

Read more

25 Sep 2025 09:30

News

Lupin receives USFDA tentative approval for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets

Lupin has received tentative approval from the United States Food and Drug Administration ...

Read more

24 Sep 2025 19:39

News

Lupin's Pune Biotech facility undergoes USFDA pre-approval inspection

The inspection concluded with 4 observations, the company said in a regulatory filing. The...

Read more

22 Sep 2025 09:31

News

Lupin's Pune Biotech unit concludes USFDA inspection

Lupin announced that USFDA has conducted a product-specific Pre-Approval Inspection at the...

Read more

20 Sep 2025 15:09

News

Lupin slides after receiving six observations from USFDA for Nagpur facility

According to a regulatory filing, the inspection was carried out from 8 September to 16 Se...

Read more

17 Sep 2025 09:17

News

Lupin receives USFDA approval for Lenalidomide Capsules

Lupin today announced that it has received approval from the United States Food and Drug A...

Read more

17 Sep 2025 18:16

SWOT Analysis Of Lupin Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Lupin Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Lupin Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Lupin Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 55,602 Cr while Market cap of Lupin Ltd is 87,731 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Lupin Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Lupin Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Lupin Ltd?

As of September 28, 2025, the Glenmark Pharmaceuticals Ltd stock price is INR ₹1970.3. On the other hand, Lupin Ltd stock price is INR ₹1920.75.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Lupin Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Lupin Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions